<DOC>
	<DOCNO>NCT02770508</DOCNO>
	<brief_summary>The purpose study compare safety efficacy combination QD regimen consist ritonavir boost darunavir ( FDC ) lamivudine versus ritonavir boost darunavir ( FDC ) plus co-formulated tenofovir emtricitabine co-formulated tenofovir/lamivudine naïve HIV-1 infected patient . Subjects ARV-naïve HIV-1-infected patient eligible start ARV therapy accord current guidelines.Subjects adult ≥ 18 year age meet inclusion criterion none exclusion criterion .</brief_summary>
	<brief_title>Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir Naïve HIV-1 Infected Subjects</brief_title>
	<detailed_description>Key Inclusion Criteria 1 . Documented HIV RNA &gt; 1000 copies/ml 2 . Subject naïve ARV . . 3 . Subject indication receive antiretroviral regimen , base local guideline . 4 . Able provide inform consent agree use highly effective non-hormonal method contraception Key Exclusion Criteria 1 . Evidence resistance Darunavir and/or FTC 3TC TDF base resistance test 2 . Patient chronic hepatitis B 3 . Subject currently active AIDS defining illness ( Category C condition accord CDC Classification System 4 . Required use disallow concomitant therapy 5 . Subject grade 3 4 laboratory abnormality define DAIDS grade table Primary Objective • Proportion patient HIV-1 RNA level less 50 copies/mL week 48 ( ITT analysis , Snapshot analysis )</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion criterion : 1 . &gt; 18 year age . 2 . Patient document HIV1 infection define positive ELISA plus confirmatory Western Blot ; alternatively , plasma HIV1 RNA ≥1,000 copies/mL ever document . 3 . Subject voluntarily sign date informed consent form , approve Institutional Review Board ( IRB ) / Independent Ethics Committee ( IEC ) , nature study explain subject opportunity ask question . The informed consent must sign studyspecific procedure perform . 4 . Subject agrees take medication study , include counter medicine herbal preparation , without approval trial physician . 5 . Documented HIV1 RNA &gt; 1,000 copies/mL 6 . Subject naïve ARV . ( Patients receive ARV ≤ 48 hour allow ) . Subject indication receive antiretroviral regimen . 7 . Subjects comply protocol requirement . 8 . Subject 's general medical condition , investigator 's opinion , interfere assessment completion trial . 9 . If patient female must breastfeed pregnant . She must either postmenopausal least one year , surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , must : use 2 different method birth control include , least , one barrier method , acceptable subject investigator , urine pregnancy test perform Screening Visit Baseline . Results test must negative . continue use 2 different method birth control include , least , one barrier method least 30 day end treatment period 10 . For male patient , must comply use barrier birth control method Study 60 day beyond Study completion Exclusion criterion : 1 . Evidence resistance 3TC DRV/r , TDF , FTC 3TC base result resistance test do screen visit , resistance consider accordance IASUSA panel , version date March 2013 . Any following mutation consider resistance DRV/r : I47V , I50V , I54M/L , L76V , I84V , 3 minor mutation : V11I , V32I , L33F , T74P , L89V . Any follow mutation consider resistance 3TC FTC : M184V/I /or K65R / Q151M . Any follow mutation consider resistance TDF : K65R , K70E , double insertion 69 3 TAMS include M41L L210W . 2 . Prior HIV2 document infection . 3 . The use disallow concomitant therapy ( see Appendix C ) . 4 . Active Hepatitis B infection ( stage ) . 5 . The patient diagnose acute active hepatitis cause , chronic hepatitis C WITH level aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 5 high upper limit normal ( ULN ) AND/OR may require oneyear treatment . 6 . Any clinical significant active disease ( instance , tuberculosis , heart failure , pancreatitis ) medical history physical examination finding , accord investigator 's opinion , may risk patient 's safety , result study adherence rule protocol . 7 . The patient active AIDSassociated opportunistic disease ( Category C accord CDC classification system HIV infection 1993 ) within 30 day screen . Stabilized patient treatment AIDSassociated opportunistic disease may include study . 8 . Life expectancy &lt; 1 year accord investigator 9 . Laboratory test perform screen visit show follow alteration : Hemoglobin &lt; 8.0 gm/dL Absolute neutrophil count ( ANC ) &lt; 750 cells/µL Platelet Count &lt; 50,000 cells/mm3 10 . The use study agent within 30 day screen . 11 . Use immunosuppressive drug , cytokine inhibitor cytokine prior year . 12 . Any condition ( include , without limitation , use alcohol drug ) investigator 's opinion may compromise safety patient his/her adherence protocol 13 . Patients pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>antiretroviral naive</keyword>
	<keyword>dual therapy</keyword>
</DOC>